Nasdaq:US$13.50 (+0.55) | HKEX:HK$21.80 (+0.60) | AIM:£2.26 (+0.09)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 6 Apr 2013

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer